Literature DB >> 21760765

Report on Notifications Pursuant to §21 German Transfusion Act for 2008 and 2009.

Olaf Henseler1, Margarethe Heiden, Birgit Haschberger, Janina Hesse, Rainer Seitz.   

Abstract

SUMMARY: This report contains the data collected in 2008 and 2009, pursuant to Section 21 German Transfusion Act as well as an overview of the supply situation during the last 10 years. In 2009, blood donation services reported a total of 7.5 million donations - the largest amount since 2000. At the same time, more than 4.7 million red blood cell (RBC) concentrates and more than 500,000 platelet concentrates were available. The number of therapeutic single plasma units decreased to 1.1 million units in 2009. The loss rate for RBC concentrates is still between 3 and 4% for the users while for the manufacturers it has decreased slightly to 1.4%. The loss rate, for platelet concentrates, on the other hand, increased in 2009, especially-what is noteworthy-for manufacturers of pooled platelet concentrates. The loss rate for apheresis platelet concentrates accounted for 5.2% compared to 17.5% for pooled platelet concentrates. As far as the users were concerned, loss rates for platelet concentrates largely remained unchanged with rates between 5 and 6%. Based on the data collected, the supply with blood components for transfusion can be regarded as assured. Nearly 2.9 million 1 of plasma for fractionation were collected in Germany in 2009. According to reports from the pharmaceutical industry, out of these, 2.6 million 1 remained on the German market, out of which only 56% were fractionated in this country. Many plasma derivatives are not manufactured in Germany, despite the large amounts of plasma collected. The supply with these products, however, is assured by imports. Overall, 16,409 autologous and 9,435 allogeneic stem cell preparations were manufactured in 2009, out of which 3,382 allogeneic preparations were exported. 3,181 autologous and 2,374 allogeneic preparations were transplanted; 187 of these products from imports. The large number of exported stem cells and the small number of imported ones suggest that no serious shortages are to be expected for the supply with these products.

Year:  2011        PMID: 21760765      PMCID: PMC3128153          DOI: 10.1159/000328949

Source DB:  PubMed          Journal:  Transfus Med Hemother        ISSN: 1660-3796            Impact factor:   3.747


  7 in total

1.  Report on Notifications Pursuant to section sign21 German Transfusion Act for 2007.

Authors:  Olaf Henseler; Margarete Heiden; Birgit Haschberger; Janina Hesse; Rainer Seitz
Journal:  Transfus Med Hemother       Date:  2010-01-22       Impact factor: 3.747

2.  Impact of demographic changes on the blood supply: Mecklenburg-West Pomerania as a model region for Europe.

Authors:  Andreus Greinacher; Konstanze Fendrich; Ulf Alpen; Wolfgang Hoffmann
Journal:  Transfusion       Date:  2007-03       Impact factor: 3.157

3.  [Regulations stability time of platelet concentration for the purpose of reducing life threatening septic transfusion reactions through bacterial contamination: from the 66th meeting of the Working Group on Blood on 9 June 2008 as adopted following (V 38)].

Authors: 
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2008-12       Impact factor: 1.513

4.  Management of blood supplies during an influenza pandemic.

Authors:  Christel Kamp; Margarethe Heiden; Olaf Henseler; Rainer Seitz
Journal:  Transfusion       Date:  2009-12-09       Impact factor: 3.157

5.  [Demography and donation frequencies of blood and plasma donor populations in Germany].

Authors:  Sabine Ritter; L Willand; B Reinhard; R Offergeld; O Hamouda
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2008-08       Impact factor: 1.513

Review 6.  Hemostatic resuscitation for massive bleeding: the paradigm of plasma and platelets--a review of the current literature.

Authors:  Pär I Johansson; Jakob Stensballe
Journal:  Transfusion       Date:  2009-11-19       Impact factor: 3.157

7.  An FFP:PRBC transfusion ratio >/=1:1.5 is associated with a lower risk of mortality after massive transfusion.

Authors:  Jason L Sperry; Juan B Ochoa; Scott R Gunn; Louis H Alarcon; Joseph P Minei; Joseph Cuschieri; Matthew R Rosengart; Ronald V Maier; Timothy R Billiar; Andrew B Peitzman; Ernest E Moore
Journal:  J Trauma       Date:  2008-11
  7 in total
  2 in total

1.  Hematopoietic Growth Factors in Transfusion Medicine and Cellular Therapy - Part II.

Authors:  Peter Schlenke; Andreas Humpe
Journal:  Transfus Med Hemother       Date:  2013-10       Impact factor: 3.747

2.  Donor satisfaction with a new german blood donor questionnaire and intention of the donor to return for further donations.

Authors:  Christian Weidmann; Michael Müller-Steinhardt; Sven Schneider; Eberhard Weck; Harald Klüter
Journal:  Transfus Med Hemother       Date:  2013-08-26       Impact factor: 3.747

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.